Exicure, Inc. (XCUR)
- Previous Close
0.4630 - Open
0.4508 - Bid --
- Ask --
- Day's Range
0.4508 - 0.4830 - 52 Week Range
0.3650 - 1.5000 - Volume
2,215 - Avg. Volume
35,068 - Market Cap (intraday)
4.177M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
0.27 - EPS (TTM)
1.7700 - Earnings Date Jul 12, 2024 - Jul 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
www.exicuretx.comRecent News: XCUR
Performance Overview: XCUR
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XCUR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XCUR
Valuation Measures
Market Cap
3.95M
Enterprise Value
8.61M
Trailing P/E
0.26
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.12
Price/Book (mrq)
0.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
12.88%
Return on Assets (ttm)
7.36%
Return on Equity (ttm)
56.40%
Revenue (ttm)
23.79M
Net Income Avi to Common (ttm)
3.06M
Diluted EPS (ttm)
1.7700
Balance Sheet and Cash Flow
Total Cash (mrq)
2.33M
Total Debt/Equity (mrq)
72.12%
Levered Free Cash Flow (ttm)
-11.54M
Research Analysis: XCUR
Company Insights: XCUR
XCUR does not have Company Insights